Microbot Medical Reports Accelerating Revenue Growth, Q2 Exceeds Q1 as Robotic System Adoption Doubles
MBOT sits 32% above its 52-week low of $1.6.
Summary
Microbot Medical announced strong commercial momentum for its LIBERTY Endovascular Robotic System, with Q2 revenue already surpassing Q1 figures and customer accounts more than doubling.
Key Events · Product Development and Regulatory · MBOT
-
Q2 Revenue Exceeds Q1
Revenue from the LIBERTY Endovascular Robotic System in the current second quarter of 2026 has already surpassed the total revenue recorded in the first quarter of 2026.
-
Accelerating System Adoption
The number of customer accounts for the LIBERTY system has more than doubled since the commencement of the Full Market Release.
-
Expanded Market Footprint
The LIBERTY system has been adopted by hospitals in six states, with Boston becoming the first city to have multiple accounts using the system.
-
Increased Recurring Orders
The company is experiencing a rise in recurring customer orders and is building a growing pipeline of potential new accounts.
Analysis · MBOT · Industrial Applications And Services
This filing provides concrete evidence of successful commercialization for Microbot Medical's LIBERTY system. The announcement that Q2 revenue has already exceeded Q1 revenue, coupled with a doubling of customer accounts, indicates strong adoption and utilization. This is crucial for a company that recently reported higher Q1 losses and increased cash burn, as it demonstrates progress towards financial sustainability and potentially reduces reliance on dilutive capital raises.
At the time of this filing, MBOT was trading at $2.11 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $145.7M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.